Inhibition of Glucose- and Calcium-Induced Insulin Secretion from βTC3 Cells by Novel Inhibitors of Protein Isoprenylation
- 1Department of Pharmaceutical Sciences, Wayne State University, and β Cell Biochemistry Research Laboratory, John D. Dingell VA Medical Center, Detroit, Michigan (R.A., H.-Q.C., M.T., A.K.); and 2Department of Medicinal Chemistry and Molecular Pharmacology, School of Pharmacy and Pharmacal Sciences, Purdue University, West Lafayette, Indiana (R.G.)
- Dr. Anjan Kowluru, Department of Pharmaceutical Sciences, Applebaum College of Pharmacy and Health Sciences, Wayne State University, 259 Mack Ave., Detroit, MI 48201. E-mail: akowluru{at}wizard.pharm.wayne.edu
Abstract
The majority of low molecular weight G proteins undergoes a series of post-translational modification steps, e.g., isoprenylation, at their C-terminal cysteine, which seem to be critical for the transport of the modified proteins to the membrane sites for interaction with their respective effector proteins. Using lovastatin, an inhibitor of mevalonic acid, and hence, isoprenoid biosynthesis, we demonstrated previously that protein isoprenylation is critical for physiological insulin secretion from normal rat islets. Herein, we used more selective synthetic inhibitors of protein prenylation to examine their effects on glucose- and calcium-mediated insulin secretion from βTC3 cells. Both 3-allyl- and vinylfarnesols, which inhibit and/or modulate protein farnesyl transferases, significantly (80–95%) inhibited glucose- and KCl-stimulated insulin secretion from these cells. In a similar manner, the allyl and vinyl forms of geranylgeraniol, reagents targeted toward protein geranylation, attenuated insulin secretion elicited by glucose and KCl. Furthermore, manumycin A, a natural inhibitor of protein farnesylation, and geranylgeranyl transferase inhibitor-2147 (GGTI-2147), a peptidomimetic inhibitor of protein geranylgeranylation, also inhibited glucose- and KCl-induced insulin secretion to comparable degrees. Treatment of βTC3 cells with either 3-vinylfarnesol or 3-vinyl geranylgeraniol resulted in accumulation of unprenylated proteins in the cytosolic fraction. These data further support our original formulation that inhibition of isoprenylation of small molecular weight G proteins might impede their interaction with their putative effectors, which may be required for physiological insulin secretion.
Footnotes
-
These studies are supported by grants from the Department of Veterans Affairs (Merit Review grant and the Research Enhancement Award Program grant; both to A.K.), the National Institutes of Health (1 R01-DK-56005-01 to A.K. and 1 R01-CA 78819-01 to R.A.G.). A.K. is the recipient of a Career Research Scientist Award from the Department of Veterans Affairs.
-
DOI: 10.1124/jpet.102.036160
- Abbreviations:
- MVA
- mevalonic acid
- LOVA
- lovastatin
- MTT
- 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
- ELISA
- enzyme-linked immunosorbent assay
- GGTI-2147
- geranylgeranyl transferase inhibitor-2147
- 3vFOH
- 3-vinylfarnesol
- 3aFOH
- 3-allylfarnesol
- 3-vGGOH
- 3-vinyl geranylgeraniol
- FTase
- farnesyltransferase
- GGTase
- geranylgeranyl transferase I
-
- Received March 13, 2002.
- Accepted May 28, 2002.
- U.S. Government



